This Specialized Program of Research Excellence (SPORE) grant is intended to support multi-project, interdisciplinary and multi-institutional translational research in glioblastoma. The governance structure of this Dana-Farber/Harvard Cancer Center (DF/HCC) SPORE grant will provide the foundation for the implementation, execution and ultimate success of all projects and cores. The Administration Core will serve as the hub for this governance structure and will aim to achieve a number of specific objectives as defined below. We will implement a plan to establish experienced, centralized program leadership and administration. The Glioma SPORE Director and Co-Director are senior administrators and researchers who have worked together on prior DF/HCC inifiatives and who provide strong, complementary leadership for the grant. The trans-institutional administrative team consists of senior personnel at DF/HCC institutions who have worked together effecfively in the preparafion of this grant applicafion. We have incorporated two senior clinical and imaging scientists into the Administrafion Core to supervise Glioma SPORE-specific clinical trials and imaging studies, respectively, and to enable this Glioma SPORE to capitalize on existing DF/HCC Cores to support these types of studies. We will establish an effective internal and external committee structure to provide expertise, advice and oversight of the program. Each of the committees consists of collaborative, complementary members who have already worked together in the preparation of this SPORE application. A series of regular Glioma SPORE meetings involving both administrative and scientific SPORE staff are planned to facilitate close collaboration, troubleshooting and monitoring of the SPORE program. We will establish an effective internal and external communicafions program, which will include a Glioma SPORE-specific component. An established and extensive DF/HCC communications infrastructure will be utilized to promote open, regular, trans-institutional communicafion regarding SPORE opportunities and activities. We will implement an active SPORE program to enhance participation by underrepresented minorities and women.

Public Health Relevance

Glioblastomas are the third leading cause of cancer-related death among middle-aged men and the fourth leading cause of death for women between 15-34 years of age (http://www.CBTRUS.org). In the fullness of time, the work that we propose with targeted therapies could change the standard of care and improve patient outcomes for these tumors. The Administrafion Core will serve as the 'hub' for the governance of this SPORE research program.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA165962-03
Application #
8936620
Study Section
Special Emphasis Panel (ZCA1-RPRB-7)
Program Officer
Arnold, Julia T
Project Start
Project End
2016-07-31
Budget Start
2015-08-01
Budget End
2016-07-31
Support Year
3
Fiscal Year
2015
Total Cost
$53,239
Indirect Cost
$13,015
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02114
Zhao, Yingchao; Liu, Pinan; Zhang, Na et al. (2018) Targeting the cMET pathway augments radiation response without adverse effect on hearing in NF2 schwannoma models. Proc Natl Acad Sci U S A 115:E2077-E2084
Bian, X; Gao, J; Luo, F et al. (2018) PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy. Oncogene 37:341-351
McBrayer, Samuel K; Mayers, Jared R; DiNatale, Gabriel J et al. (2018) Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma. Cell 175:101-116.e25
McKenney, Anna Sophia; Lau, Allison N; Somasundara, Amritha Varshini Hanasoge et al. (2018) JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition. J Clin Invest 128:789-804
Shankar, Ganesh M; Kirtane, Ameya R; Miller, Julie J et al. (2018) Genotype-targeted local therapy of glioma. Proc Natl Acad Sci U S A 115:E8388-E8394
Arvanitis, Costas D; Askoxylakis, Vasileios; Guo, Yutong et al. (2018) Mechanisms of enhanced drug delivery in brain metastases with focused ultrasound-induced blood-tumor barrier disruption. Proc Natl Acad Sci U S A 115:E8717-E8726
Li, Ben B; Qian, Changli; Roberts, Thomas M et al. (2018) Targeted Profiling of RNA Translation. Curr Protoc Mol Biol :e71
Nowosielski, Martha; Wen, Patrick Y (2018) Imaging Criteria in Neuro-oncology. Semin Neurol 38:24-31
Li, Ben B; Qian, Changli; Gameiro, Paulo A et al. (2018) Targeted profiling of RNA translation reveals mTOR-4EBP1/2-independent translation regulation of mRNAs encoding ribosomal proteins. Proc Natl Acad Sci U S A 115:E9325-E9332
Khandekar, Melin J; Jain, Rakesh (2018) Smooth sailing for immunotherapy for unresectable stage III non-small cell lung cancer: the PACIFIC study. Transl Cancer Res 7:S16-S20

Showing the most recent 10 out of 84 publications